Sven Guenther

As Chief Scientific Officer, Dr. Guenther leads KemPharm’s research team and plays a central role in the advancement of the company’s pipeline of prodrugs and the development of new products that utilize KemPharm’s proprietary LAT® discovery technology to improve one or more of the attributes of approved drugs.

Prior to joining KemPharm, Dr. Guenther served as a research scientist for New River Pharmaceuticals, where he was part of the development team for Vyvanse®. He is an inventor on a number of patents and patent applications and author of several research papers.

Dr. Guenther received his Ph.D. degree from the University of Iowa.